Comparison

CJC-1295 vs. Sermorelin

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

CJC-1295

Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.

Sermorelin

Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.

Evidence base

Highest evidence

Human trial

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	CJC-1295	Sermorelin
Germany	Unapproved	Unapproved
United States	Research only	Research only

Full entries

Frequently asked questions

What is the difference between CJC-1295 and Sermorelin?: CJC-1295 is classified as "Growth", while Sermorelin is classified as "Growth". CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. Sermorelin: Synthetic analogue of the first 29 amino acids of human GHRH. Stimulates pulsatile growth-hormone secretion from the pituitary. Formerly FDA-approved as Geref Diagnostic, now withdrawn in many markets — compounding and research use dominate. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CJC-1295 or Sermorelin?: The highest available evidence level is "Human trial" for CJC-1295 and "Human RCT" for Sermorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CJC-1295 and Sermorelin in Germany and the United States?: Germany: CJC-1295 — Unapproved, Sermorelin — Unapproved. United States: CJC-1295 — Research only, Sermorelin — Research only. These are factual summaries with source and review date on the individual pages.

Country

CJC-1295

Sermorelin

Germany

Unapproved

United States

Research only

Frequently asked questions

What is the difference between CJC-1295 and Sermorelin?

CJC-1295 is classified as "Growth", while Sermorelin is classified as "Growth". CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. Sermorelin: Synthetic analogue of the first 29 amino acids of human GHRH. Stimulates pulsatile growth-hormone secretion from the pituitary. Formerly FDA-approved as Geref Diagnostic, now withdrawn in many markets — compounding and research use dominate. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CJC-1295 or Sermorelin?

The highest available evidence level is "Human trial" for CJC-1295 and "Human RCT" for Sermorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CJC-1295 and Sermorelin in Germany and the United States?

Germany: CJC-1295 — Unapproved, Sermorelin — Unapproved. United States: CJC-1295 — Research only, Sermorelin — Research only. These are factual summaries with source and review date on the individual pages.